Literature DB >> 21470236

Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency.

Deirdra R Terrell1, David G Motto, Johanna A Kremer Hovinga, Bernhard Lämmle, James N George, Sara K Vesely.   

Abstract

BACKGROUND: It has been postulated that blood group O subjects may be partially protected against thrombotic thrombocytopenic purpura (TTP) because they have lower plasma levels of von Willebrand factor. STUDY DESIGN AND METHODS: The Oklahoma TTP Registry enrolled 301 consecutive patients from November 13, 1995 (when systematic ADAMTS13 measurements began), through 2009; 281 (93%) patients had ADAMTS13 measurements. Patients were designated as having severe ADAMTS13 deficiency when the activity measurement by either method was less than 10%. ABO blood group was determined in all 281 patients. The observed frequency of blood group O was compared to the expected frequency. The association between severe ADAMTS13 deficiency and blood group, race, sex, and age were analyzed by logistic regression.
RESULTS: The frequency of blood group O was unexpectedly and significantly greater than the race-ethnicity-adjusted expected frequency in 65 patients with severe ADAMTS13 deficiency (60.0% vs. 47.4%, p = 0.042) but not in 216 patients without severe ADAMTS13 deficiency (44.9% vs. 46.5%, p = 0.639). Blood group O and race-ethnicity were independently associated with severe ADAMTS13 deficiency among patients with TTP. The probability for severe ADAMTS13 deficiency was 45.8% with O and 32.1% with non-O blood groups for black patients and 24.1% with O and 15.1% with non-O blood groups for white patients.
CONCLUSION: Among patients with TTP and severe ADAMTS13 deficiency the relative frequency of patients with blood group O was greater than expected, suggesting that blood group O may be a risk factor for TTP associated with severe ADAMTS13 deficiency.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470236      PMCID: PMC3151471          DOI: 10.1111/j.1537-2995.2011.03125.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  25 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States.

Authors:  George Garratty; Simone A Glynn; Robin McEntire
Journal:  Transfusion       Date:  2004-05       Impact factor: 3.157

3.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

4.  An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13.

Authors:  D J Bowen
Journal:  J Thromb Haemost       Date:  2003-01       Impact factor: 5.824

5.  Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Authors:  Valentina Bianchi; Rodolfo Robles; Lorenzo Alberio; Miha Furlan; Bernhard Lämmle
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

6.  Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease.

Authors:  Pier Mannuccio Mannucci; Cristina Capoferri; Maria Teresa Canciani
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

7.  The effect of ABO blood group on the diagnosis of von Willebrand disease.

Authors:  J C Gill; J Endres-Brooks; P J Bauer; W J Marks; R R Montgomery
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  ABO blood group genotype and plasma von Willebrand factor in normal individuals.

Authors:  M Shima; Y Fujimura; T Nishiyama; T Tsujiuchi; N Narita; T Matsui; K Titani; M Katayama; F Yamamoto; A Yoshioka
Journal:  Vox Sang       Date:  1995       Impact factor: 2.144

9.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

10.  Measurement of von Willebrand factor activity: relative effects of ABO blood type and race.

Authors:  C H Miller; E Haff; S J Platt; P Rawlins; C D Drews; A B Dilley; B Evatt
Journal:  J Thromb Haemost       Date:  2003-10       Impact factor: 5.824

View more
  10 in total

Review 1.  Thrombotic thrombocytopenic purpura: a review of the literature in the light of our experience with plasma exchange.

Authors:  Claudia Rizzo; Sergio Rizzo; Elisabetta Scirè; Danilo Di Bona; Carlo Ingrassia; Giovanni Franco; Roberto Bono; Gerlando Quintini; Calogero Caruso
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

2.  What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

3.  Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura.

Authors:  Lova Sun; Johnathan Mack; Ang Li; Justine Ryu; Vivek A Upadhyay; Lynne Uhl; Richard M Kaufman; Christopher P Stowell; Walter S Dzik; Robert S Makar; Pavan K Bendapudi
Journal:  Blood Adv       Date:  2019-05-14

4.  Reference range for ADAMTS13 antigen, activity and anti-ADAMTS13 antibody in the healthy adult Singapore population

Authors:  Allison Ching Yee Tso; Christina Lai Lin Sum; Kiat Hoe Ong
Journal:  Singapore Med J       Date:  2020-06-26       Impact factor: 3.331

5.  Re-examination of 30-day survival and relapse rates in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  Cassiana E Bittencourt; Jennifer P Ha; Robert W Maitta
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

Review 6.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Authors:  Johana Hrdinová; Silvia D'Angelo; Nuno A G Graça; Bogac Ercig; Karen Vanhoorelbeke; Agnès Veyradier; Jan Voorberg; Paul Coppo
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

7.  Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality.

Authors:  Raima Memon; Jingrui Sui; Chen Lin; X Long Zheng
Journal:  TH Open       Date:  2021-01-13

8.  Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker.

Authors:  Ralph Wendt; Sven Kalbitz; Felix Otto; Tanja Falter; Joachim Beige; Heidi Rossmann; Bernhard Lämmle
Journal:  Front Med (Lausanne)       Date:  2021-02-26

Review 9.  The relationship between ABO blood group, von Willebrand factor, and primary hemostasis.

Authors:  Soracha E Ward; Jamie M O'Sullivan; James S O'Donnell
Journal:  Blood       Date:  2020-12-17       Impact factor: 22.113

10.  Thrombotic thrombocytopenic purpura secondary to ABO group incompatible blood transfusion in a patient after cardiac surgery.

Authors:  Yalcin Solak; Nedim Yilmaz Selcuk; Abduzhappar Gaipov; Ramazan Ucar; Zeynep Biyik; Kadir Acar
Journal:  Indian J Crit Care Med       Date:  2013-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.